Details
Category: Volume 07 Issue 09 September 2019
Hits: 1127

Title: Association of uric acid and dyslipidemia in newly detected type 2 Diabetes Mellitus

Authors: Suman Doddamani, Veni U

 DOI: https://dx.doi.org/10.18535/jmscr/v7i9.36

Abstract

    

Background: Cardiovascular disease has been suggested to be associated with higher levels of serum uric acid. Dylipidemia in Diabetes mellitus has been linked with cardiovascular complications in these patients. We undertook this study to evaluate the association of uric acid and dyslipidemia in newly detected type 2 Diabetes Mellitus.

Materials and Methods: The study group comprised of 100 newly detected type 2 diabetic patients in the age group of 30-60 years visiting medicine Out Patient Department. As a control group 100 age and sex matched healthy participants were taken. The blood samples were used for measuring various parameters. Serum uric acid was estimated by uricase method. LCAT activity was assessed by measuring the difference between esterified and free Cholesterol. Determination of free and esterified cholesterol was done by using digitonin precipitation method. HDL cholesterol level and total cholesterol was measured by Cholesterol oxidase Peroxidase method. Triacylglycerol estimation was done by Glycerol 3-Phosphate Oxidase – Peroxidase method. VLDL and LDL cholesterol was calculated by formula. Fasting blood glucose was measured by Glucose Oxidase Peroxidase method.

Results: Study found that serum uric acid, LDL, VLDL, Total Cholesterol, Triacylglycerol were significantly increased in type 2 DM when compared to control group. Activity of LCAT and levels of HDL were significantly decreased in newly detected type 2 DM when compared to control group.

Conclusion: Hyperuricemia is found to be associated with dyslipedimia along with decreased LCAT activity in Diabetes mellitus patients. Thus uric acid can be used as a potential biomarker of deterioration of glucose metabolism and dyslipedemia. 

References

  1. Alvarez, Lario B, Macrron Vincents. Is there anything good in uric acid? Q J Med. 2011;104(12):1015-1024.
  2. Glantzounis CK, Tsimoyiannis, E C Kappan. Uric acid and oxidative stress. Curr Pharm Des. 2005;11(32):4145-4155.
  3. Watanabe, S. Kang. Uric acid, and the pathogenesis of salt-sensitivity. Hypertension.2002:40:355-360.
  4. Fauci, Braunwald, Kasper, Hauser, Longo Jameson, Loscalzo. Diabetes Mellitus. In Harrison’s Principles of Internal Medicine, 17th Mc Graw-Hill Newyork, 2008;2290-2301.
  5. Mosaad A. Abou-Seif. Evaluation of some biochemical changes in diabetic patients. Clinica Chimica Acta. 2004;346:161–170.
  6. Francesehini G, Maderna P, Sirtori CR. Reverse Cholesterol Transport Physiology and Pharmacology. Atherosclerosis. 1991;88:99-107.
  7. Labri Krimbout, Michel Marcil, Jean Davignon, Jacques Genest. Interaction of LCAT alpha 2- Macroglobulin Complex with Low Density Lipoprotein Receptor –related The Journal of Biological Chemistry. 2001;276(35):33241-33248.
  8. Kwiterovich PO. The anti atherogenic role of high-density lipoprotein cholesterol. Am J Cardiol. 1998;82:13-21.
  9. Franceschini G, Maderna P, Sirtori CR. Reverse cholesterol transport: physiology and pharmacology. Atherosclerosis. 1991;88:99-107.
  10. Nader Rifai G, Russell Warnick. Creatinine, Urea, and Uric acid: In: Teitz textbook of clinical and Molecular Diagnostics. 4th ed W.B. Saunders., Philadelpia 2006;371.
  11. Gowland E, editors. Varley’s Practical Clinical Biochemistry. 4th New Dehli: CBS;2005:311-313.
  12. Nader Rifai, Russell Warnick G. Lipids, Lipoproteins, Apolipoproteins, and other cardiovascular risk factors: In: Teitz textbook of clinical and Molecular Diagnostics. 4th ed W.B. Saunders., Philadelpia 2006; 940-949.
  1. Nader Rifai G, Russell Warnick. Carbohydrates: In: Teitz textbook of clinical and Molecular Diagnostics. 4th ed W.B. Saunders., Philadelpia 2006;870.
  2. Zoppini G, Tanger G, Negri C, Perrone F. Eleveted serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetes. Diabetes care. 2009;32:1716-1720.
  3. Nakanishi N, Okarnoto M, Yoshida H. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type 2 diabetes in Japanese male office workers. Eur. J. Epidemiol. 2003;18(6):523-530.
  4. Boyko EJ,De Courten, Zimmet P.Z. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care. 2000;23(9):1242-1248.
  5. Dehgan A, Van Hoek M, Hofman A. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes care.2008;31(2):361-362.
  6. Facchini F, Chen YD, Hollenbeck CB aand Reaven GM. Relationship between resistance to insulin mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA.1991;266:3008-3011.
  7. Durucan M, Serdar Z, Sarand LE, Surmen Gur E. LCAT activity and cholesterol ester transfer rate in patients with Diabetes Mellitus. Turk J Med Sci 2003; 33:95-101.
  8. Ghanei A, Esfananian F, Esteghamati A, Behjati J, Hamadi S, Nakhjavani M. LCAT activity is decreased in type 2 Diabetes Mellitus. Acta Medica Iranica 2007; 45(6):481-486.
  9. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relation-ship between  resistance  to  insulin-mediated  glucose  uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA1991;266:3008–11.
  10. Nakagawa T, Tuttle  KR,  Short  RA,  Johnson    Fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nat Clin Nephrol2005;1:80–6.
  11. Kanellis J, Kang    Uric acid  as  a  mediator  of  endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol2005;25:39–42.

Corresponding Author

Veni U

Research Assistant, Department of Biochemistry, Sanjay Gandhi Institute of Trauma and Orthopaedics, Bangalore, Karnataka, India